Introduction
Patients with atrial fibrillation (AF) have a five-fold increased risk of stroke/thromboembolism (TE), 1 but the stroke/TE and mortality risks are reduced if patients are treated with prophylactic oral anticoagulation (OAC). 2, 3 For decades, vitamin K antagonists (VKAs) were the only option for OAC treatment until non-VKA oral anticoagulants (NOACs) were approved as stroke/TE prophylaxis. 4 Dabigatran was introduced to the Danish market on 22 August 2011, followed by rivaroxaban on 6 February 2012, and apixaban on 10 December 2012. The approvals of NOACs were based on three large randomized Phase III trials evaluating either dabigatran, rivaroxaban, or apixaban vs. warfarin in AF, respectively. [5] [6] [7] The results from the trials showed that all NOACs were at least non-inferior to warfarin in prevention of stroke/TE. Intracranial bleeding was a safety outcome in the trials and the NOACs all showed lower rates of intracranial bleeding compared with warfarin. However, the trials were designed differently, with variations in the inclusion/exclusion criteria and either one dose or a low/high dose of the NOAC drug. Some of these differences have challenged the ability to directly compare stroke/TE prophylaxis and risk of intracranial bleeding with dabigatran, rivaroxaban, or apixaban relative to warfarin. Importantly, results from randomized controlled trials are wholly convincing, but comparative effectiveness and intracranial bleeding data are sparse in 'real-world' patients. The aim of this study was to examine the risk of stroke/TE and intracranial bleeding associated with dabigatran, rivaroxaban, and apixaban compared with VKA, among patients with non-valvular AF in a nationwide cohort.
Methods

Data sources
The Danish National Patient Registry holds data on all hospital admissions and contacts since 1978. 8 The International Classification of Diseases (ICD) (the 10th revision) is used to code diagnosis codes related to the hospital admission or contact. The Danish National Prescription Registry keeps data on all prescriptions dispensed from a pharmacy. 9 The Danish Civil Registration System records vital status and date of death. 10 All
Danes are at birth or immigration registered with a unique personal identification number and we used this number to cross-link individual information from the administrative registries.
Study design and study population
This was an observational study and the study period was from 22 August 2011 until 31 December 2015. AF patients with no previous OAC treatment before the study period were included on the day they filled a first-time prescription for VKA, dabigatran, rivaroxaban, or apixaban during the study period. The exclusion criteria were (i) age <30 years or >100 years, (ii) valvular AF, (iii) total hip or knee arthroplastics within 5 weeks before inclusion day, (iv) pulmonary embolism or deep vein thrombosis within 6 months before inclusion day, or (v) two prescriptions of different OAC claimed at the inclusion day.
Concomitant pharmacotherapy and comorbidity
Concomitant pharmacotherapy was identified from prescriptions dispensed 180 days before the inclusion day. Comorbidities were defined from diagnosis codes recorded within 10 years prior to the inclusion day (see Supplementary material online, 
Outcomes and follow-up
Stroke/TE and intracranial bleeding were the outcomes of interest. When a patient is hospitalized due to stroke/TE or intracranial bleeding, doctors record the diagnosis code in The Danish National Patient Registry. Stroke/TE was defined as a hospitalization with an ICD-10 code of cerebral infarction, unspecified cerebral infarction, arterial embolism and thrombosis, other transient cerebral ischaemic attacks and related syndromes, and unspecified transient cerebral ischaemic attack. A validation study of the diagnosis codes for stroke/TE showed that the positive predictive value (PPV) of ischaemic stroke was 97-100% and the PPV of transient ischaemic attack was 57.9-68.5%. 11 In addition, a specified ischaemic stroke outcome was defined solely including the diagnosis code of cerebral infarction. Intracranial bleeding was defined as intracerebral haemorrhage, non-traumatic/traumatic subarachnoid haemorrhage, traumatic subdural haemorrhage, and traumatic epidural haemorrhage. Patients were followed from the day of initiation of first-time OAC treatment until the occurrence of what came first within the first 2 years: outcome, death, emigration, shift or discontinuation of OAC treatment, or 31 December 2015. Shift of OAC treatment was recorded on the day the second drug was dispensed. Discontinuation of initiated OAC treatment was defined as no consecutive prescription dispensed within 30 days since the last prescription expired.
Statistical analysis
Characteristics of the study population were presented as count, percentage and v 2 test, median, inter-quartile ranges (IQR) and KruskalWallis rank sum test, or mean and standard deviation (SD) and analysis of variance.
Only events within the first 2 years were included. The absolute outcome risks were estimated using the Aalen-Johansen estimator, accounting for the competing risks of death and shift/discontinuation of OAC treatment. Multiple outcome-specific Cox regression was performed to model effects of treatment (dabigatran, rivaroxaban, and apixaban using the VKA group as reference) on the outcome-specific hazard rates. In all Cox regression analyses the baseline hazard function was stratified by calendar year. For outcomes stroke/TE and ischaemic stroke, models were adjusted for the variables of the CHA 2 DS 2 -VASc score. For the intracranial bleeding outcome, the models were further adjusted for the variables of the HAS-BLED score. We report outcome-specific hazard ratios (HRs) with 95% confidence limits. From multiple Cox regression also patient-specific absolute risks were evaluated after 6 months and 1 year for each outcome. 12 Reported were average treatment effects with 95% bootstrap confidence limits (1000 bootstrap data sets) as differences of the absolute risks standardized to each of the treatments (g-formula 13 ). Within the limitations of our available data and models, the average treatment effects can be interpreted as what one would have observed in a randomized clinical trial. 13 A P-value below 0.05 was considered statistically significant. 
Results
Inclusion and follow-up Table 1 provides the characteristics of the four OAC treatment groups. The median age was lowest in the dabigatran group (71 years) and highest in the apixaban group (76 years). The lowest mean CHA 2 DS 2 -VASc and HAS-BLED scores (SD) were found in the dabigatran group with scores of 2.7 (1.6) and 2.0 (1.2), respectively, whereas the apixaban group had the highest mean CHA 2 DS 2 -VASc score of 3.1 (1.6) and the apixaban and the VKA groups both had the highest HAS-BLED score (SD) being 2.2 (1.2). Among those receiving low-dose NOAC (9322/25 205), the patients' age was !80 years in 66.2% of cases (dabigatran 61.3%; rivaroxaban 64.3%, and apixaban 77.1%).
Study population characteristics
Stroke/thromboembolism outcome
In total, 1054 suffered from stroke/TE during the patient-specific follow-up limited to the first 2 years after initiation of OAC treatment. Figure 2 illustrates the unadjusted absolute risks of stroke/TE and Table 2 reports the standardized absolute risks of stroke/TE based on multiple cause-specific Cox regression. VKA had the lowest standardized 1-year risks of stroke/TE of 2.01%, whereas apixaban had the highest being 2.46%; however, the absolute risk was not significantly different between VKA and each NOAC ( Table 2) . The outcomespecific HRs for the different OAC groups are shown in Figure 3 .
Ischaemic stroke outcome
Of the 1054 strokes/TE, 536 were coded as ischaemic stroke. The unadjusted and standardized absolute risks of ischaemic stroke are shown in Figure 4 and Table 2 , respectively. The standardized absolute risks were not significantly different between VKA and each NOAC. The adjusted HRs of associated ischaemic stroke risk were similar to the results for stroke/TE, as shown in Figure 3 .
Intracranial bleeding outcome
During the patient-specific follow-up, 261 patients suffered from intracranial bleeding. The unadjusted absolute risks were lowest for dabigatran, and the standardized absolute risks of intracranial bleeding at 1 year remained to be lowest for dabigatran (0.26%) followed by apixaban (0.40%), rivaroxaban (0.47%), and VKA (0.60%) ( Figure 5 and Table  2 ). Only dabigatran and apixaban treatment had a significantly lower absolute risk compared with VKA. Figure 3 includes the adjusted HR, where the risk of intracranial bleeding was significantly lower for the dabigatran, rivaroxaban, and apixaban groups compared with VKA.
Sensitivity analyses
Several sensitivity analyses were performed. At first, the models were tested for additional potential confounders such as chronic kidney disease and cancer. Second, the models were performed with a limited study period from 1 January 2013 until 31 December 2015. This was done to test the models in a period, where all the OAC agents were available on the Danish market. Third, subgroup analyses were performed including high stroke (CHA 2 DS 2 -VASc ! 2) and high bleeding (HAS-BLED > 3) risk patients. Finally, we analysed stroke without considering shift or discontinuation of initiated OAC treatment as competing risk (the intention-to-treat principle). The results from the sensitivity analyses are shown in Table 3 , and the results were comparable to the results shown in Figure 3 . However, in the subgroup analysis including patients with high stroke and bleeding risks, only dabigatran treatment remained associated with a significant lower hazard rate of intracranial bleeding [HR 0.23 (95% CI 0.10-0.53)]. No significant changes of NOAC effects were seen when accounting for NOAC dose in multiple Cox regression: stroke/TE (P ¼ 0.246), ischaemic stroke (P ¼ 0.6892), and intracranial bleeding (P ¼ 0.1681). Supplementary material online, Table S2 includes a subgroup analysis of high or low dose of NOACs.
Discussion
In this nationwide cohort study including 43 299 OAC-naïve AF patients initiating VKA or an NOAC, our principal results show that 
patients initiating dabigatran, rivaroxaban, and apixaban had an associated absolute risk difference of stroke/TE that was not significantly lower than VKA. Importantly, the associated absolute risk difference of intracranial bleeding was only significantly lower among patients initiating dabigatran and apixaban compared with VKA.
Our study is complementary to the large randomized Phase III trials, providing with new aspects regarding the 'real-world' absolute risks of ischaemic and haemorrhagic stroke with NOACs vs. VKA. The inclusion and exclusion criteria in our study were broadly similar for patients initiating an NOAC or VKA treatment, and this gave a straightforward opportunity to directly compare the OAC treatment regimens, which is in contrast to the randomized trials. Moreover, 'real-world' fragile patients may have been included in our nationwide cohort (e.g. patients with increased risk of bleeding, liver disease, and chronic kidney disease) and these patients would be less represented in the trials. 14 Our nationwide data enable a generalizable interpretation of the absolute risks to other populations similar to the Danish population, i.e. predominantly Caucasian populations in Europe and North America. 15 The VKAs offer various disadvantages, including many drug and food interactions, as well as the on-going monitoring that necessitate strict patient adherence. 16 NOACs overcome some of the difficulties with VKAs, and the uptake of NOACs increased rapidly among patients with AF after their introduction to the market. 17 Disability and fatality may be the consequence of stroke, regardless of the type of stroke, and with VKA and three available NOAC drugs now on the market, the clinical question has been asked: 'Which oral anticoagulant should we use?'. propensity score weights to the statistical analyses and their results were similar to our results, 20 which suggests that in real-world practice dabigatran is associated with a similar risk of stroke as VKA, but the risk of intracranial bleeding is lower with dabigatran. Also, we found that among patients with high stroke and bleeding risks, dabigatran was the only NOAC associated with the persistence of a significant low risk of intracranial bleeding. We found the greatest difference in absolute 1-year risks of intracranial bleeding between VKA and dabigatran. The ROCKET-AF trial investigated rivaroxaban 20 mg vs. warfarin in AF patients at moderate-to-high risk for stroke, 6 and in the intention-to-treat population the HR (95% CI) of stroke was 0.88 (95% CI 0.75-1.03) for rivaroxaban compared with warfarin, in concordance with our result in Figure 3 and the intention-to-treat sensitivity analysis ( Table 3) . In the ROCKET-AF trial, patients ontreatment had an HR (95% CI) for stroke of 0.79 (0.66-0.96). Even though our study method in the main analysis was comparable to the on-treatment population in the ROCKET-AF trial, we were not able to replicate the results from the ROCKET-AF trial in a 'real-world' population. In our study the rivaroxaban group comprised patients treated with low and high dose of rivaroxaban, and suboptimal dose might have made an impact on why we did not find a significantly lower risk of stroke/TE with rivaroxaban vs. warfarin. Our analyses showed a significantly lower intracranial bleeding hazard for rivaroxaban compared with VKA. The absolute 1-year risks of intracranial bleeding however did not differ significantly between rivaroxaban and VKA. These findings do not contradict each other, because the standardized absolute 1-year risks depend not only on the hazard of intracranial bleeding but also on the hazard of death, the hazard of discontinuation/shift of treatment, the baseline hazards, and the case mix in our population. If rivaroxaban was used inappropriately, e.g. high dose prescribed a patient with a high bleeding risk, this could influence these results for intracranial bleeding.
In this study the apixaban group had the highest predicted risk score of stroke (CHA 2 DS 2 -VASc ¼ 3.11 at baseline) compared with the other OAC treatment regimens, mainly as a consequence of the highest median age and prior stroke/TE before initiating OAC treatment. Accordingly, the apixaban group had the highest absolute risk Figure 4 Unadjusted absolute risks of iscaemic stroke. of stroke/TE, but the standardized absolute risk for apixaban was not significantly increased compared with VKA. Also, the multiple Cox regression showed that the apixaban group had a similar associated hazard rate of stroke/TE as VKA. Confounding by indication is a known limitation in observational studies, and could explain why we did not find significant lower risks of stroke/TE with apixaban vs. warfarin, as in the Phase III randomized trial. 7 We did not have information about TTR or INR among patients treated with VKA. It is possible that within the recent years the selection of patients who are able to manage VKA treatment has improved, because those patients who previously were a potentially 'VKA trouble' patient are now put on an NOAC. Thus, VKA treatment would perform better simply because patients treated with VKA are selected to be more suited for VKA treatment. This practice could potentially have underestimated the true prophylactic and safety effects of NOACs in our study. Low-dose NOAC was prescribed in 40.5%, 29.2%, and 36.0% in the dabigatran, rivaroxaban, and apixaban groups, respectively. When a patient's age !80 years, Danish guidelines recommend low dose of dabigatran and apixaban (for apixaban an additional factor is needed being either body weight 60 kg or serum creatinine !133). 21 We found that among those treated with low-dose dabigatran or apixaban, age was !80 years in 61.3% and 77.1%, respectively. Low-dose NOAC treatment is also recommended for other reasons, such as moderate/severe renal impairment, but we did not have data to test whether low dose was given appropriately in these cases. We tested for interactions between high-or low-dose NOACs and the associated risk of outcomes, but the results revealed no significant interactions between NOAC dose and the associated risks of stroke/TE, ischaemic stroke, or intracranial bleeding. Again, we had no information about how well VKA therapy was managed in this study, because we had no data on TTR and INR.
It is possible that some patients were treated with suboptimal NOAC dose, e.g. low-dose NOAC prescribed without an indication for low dose. This could influence the results in our study in the direction for a lower associated risk of intracranial bleeding with NOACs without benefits in stroke prevention compared with VKA.
The stroke/TE outcome was accompanied by an ischaemic stroke outcome solely based on the diagnosis code of cerebral infarction. Then, the absolute risks were lower and in accordance with the results of other studies and trials. [5] [6] [7] 22 Limitations This registry-based study had two main limitations being (i) the observational study design and (ii) risk of residual confounding. In an observational study confounding by indication can occur. The interpretation of the average treatment effects is limited to the available data and relies on the no unobserved confounder assumption. Residual confounding however could in this study be caused by unmeasured variables, such as INR, kidney function, haemoglobin levels, and body weight.
Discontinuation or shift may have potential for unwanted side effects and unexpected outcomes that could under-or overestimate the associated risk of stroke/TE. We therefore treated discontinuation and shift as competing risks by stopping the follow-up in patients who discontinued or shifted OAC treatment. In this way, our results do not depend on events that happened after discontinuing and changing treatment. In addition, the intention-to-treat analysis showed results similar to our main results.
Another limitation lied in the unequal length of the study period for the OAC treatment groups. The rivaroxaban and apixaban groups had a shorter follow-up period than the VKA and dabigatran groups. We limited the follow-up period to maximum 2 years and tested the models (Table 3 ) with a limited study period with all the NOACs available (year 2013-15) to avoid this limitation. A doctor's awareness of bleeding risk with OAC treatment is assumed to be independent on the specific OAC agent. However, there is a risk of detection bias due to an unbalanced reporting of events between the OAC treatment groups. For example if intracranial bleeding was less likely to be detected when patients were treated with NOACs, this would lead to an overestimation of the true risk of intracranial bleeding with NOACs vs. VKA.
Conclusions
Among anticoagulant-naïve patients with AF, treatment with dabigatran, rivaroxaban, and apixaban was not associated with significant lower risk of stroke/TE, but only treatment with dabigatran and apixaban was associated with significant lower risk of intracranial bleeding, compared with VKA.
